AI Engines For more Details: Perplexity Kagi Labs You
Endocrine Disruption: BPA has been shown to mimic or interfere with the action of endogenous hormones such as estrogen, androgen, and thyroid hormones. BPA can bind to hormone receptors, alter hormone synthesis and metabolism, and disrupt hormone signaling pathways, leading to dysregulation of endocrine function. Exposure to BPA during critical periods of development, such as fetal development and early childhood, may increase the risk of reproductive and developmental disorders, including impaired fertility, altered sexual development, and adverse pregnancy outcomes.
Reproductive Health: BPA exposure has been associated with reproductive health problems in both males and females. In males, BPA exposure has been linked to reduced sperm quality, decreased sperm motility, and altered reproductive hormone levels, which may impair fertility and reproductive function. In females, BPA exposure has been associated with menstrual cycle irregularities, ovarian dysfunction, and adverse pregnancy outcomes such as miscarriage, preterm birth, and preeclampsia.
Metabolic Disorders: BPA exposure has been implicated in the development of metabolic disorders such as obesity, insulin resistance, and type 2 diabetes. BPA can disrupt adipocyte (fat cell) function, promote adipogenesis (formation of fat cells), and alter glucose and lipid metabolism, leading to increased fat accumulation, insulin resistance, and dyslipidemia. Animal studies have shown that prenatal and neonatal exposure to BPA can predispose offspring to metabolic dysfunction later in life, suggesting a potential role in the developmental origins of metabolic disorders.
Cardiovascular Disease: Emerging evidence suggests that BPA exposure may increase the risk of cardiovascular disease (CVD) by promoting endothelial dysfunction, inflammation, oxidative stress, and dyslipidemia. BPA can disrupt vascular function, impair nitric oxide signaling, and promote atherosclerosis (hardening and narrowing of arteries), which are key contributors to the development of CVD. Epidemiological studies have reported associations between BPA exposure and increased risk of hypertension, coronary artery disease, and stroke, although further research is needed to establish causality.
Neurodevelopmental Disorders: BPA exposure during critical periods of brain development has been associated with neurobehavioral abnormalities, cognitive deficits, and neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). BPA can disrupt neuronal growth, synaptogenesis, and neurotransmitter function, leading to alterations in brain structure and function. Animal studies have shown that prenatal and early postnatal exposure to BPA can impair learning and memory, alter social behaviors, and increase the risk of neurodevelopmental disorders in offspring.
Cancer: Although the evidence is still evolving, some studies suggest that BPA exposure may be associated with an increased risk of certain cancers, including breast cancer, prostate cancer, and ovarian cancer. BPA has been shown to promote carcinogenesis (cancer formation) through multiple mechanisms, including estrogenic activity, oxidative stress, inflammation, and epigenetic alterations. Human studies examining the link between BPA exposure and cancer risk have yielded mixed results, highlighting the need for further research to clarify the relationship.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | -0.4 | |
Acne | 0.4 | 0.4 | |
ADHD | 0.8 | 0.8 | 0 |
Allergic Rhinitis (Hay Fever) | 0.4 | 1.1 | -1.75 |
Allergies | 0.4 | 2.2 | -4.5 |
Allergy to milk products | 0.6 | 0.8 | -0.33 |
Alopecia (Hair Loss) | 0.8 | -0.8 | |
Alzheimer's disease | 2 | 3.9 | -0.95 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 1.6 | -3 |
Ankylosing spondylitis | 1.6 | 1.2 | 0.33 |
Anorexia Nervosa | 0.6 | 0.2 | 2 |
Antiphospholipid syndrome (APS) | 0.2 | -0.2 | |
Asthma | 1.8 | 1.4 | 0.29 |
Atherosclerosis | 0.6 | 0.2 | 2 |
Atrial fibrillation | 1.7 | 1.1 | 0.55 |
Autism | 5 | 4.2 | 0.19 |
Barrett esophagus cancer | 0.8 | 0.8 | |
Bipolar Disorder | 0.6 | 0.8 | -0.33 |
Brain Trauma | 2.1 | 2.1 | |
Carcinoma | 1.6 | 2.1 | -0.31 |
Celiac Disease | 2.4 | 1.9 | 0.26 |
Cerebral Palsy | 1 | 0.8 | 0.25 |
Chronic Fatigue Syndrome | 0.8 | 2.8 | -2.5 |
Chronic Kidney Disease | 1.4 | -1.4 | |
Chronic Lyme | 0.6 | 0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | -0.2 | |
Chronic Urticaria (Hives) | 0.8 | 0.6 | 0.33 |
Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
Colorectal Cancer | 1.2 | 3.2 | -1.67 |
Constipation | 0.8 | 2.1 | -1.63 |
Coronary artery disease | 1.6 | -1.6 | |
COVID-19 | 5.4 | 4.4 | 0.23 |
Crohn's Disease | 4.1 | 4.8 | -0.17 |
cystic fibrosis | 0.6 | 0.6 | |
Depression | 5.6 | 5.3 | 0.06 |
Eczema | 0.2 | 1.5 | -6.5 |
Endometriosis | 0.4 | 0.8 | -1 |
Epilepsy | 1.8 | 2.6 | -0.44 |
Fibromyalgia | 0.8 | 0.8 | |
Functional constipation / chronic idiopathic constipation | 1.8 | 3.8 | -1.11 |
gallstone disease (gsd) | 0.2 | -0.2 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 1.1 | -4.5 |
Generalized anxiety disorder | 0.9 | 0.9 | |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 0.2 | 0.2 | |
Gout | 2 | -2 | |
Graves' disease | 2.6 | -2.6 | |
Halitosis | 1 | -1 | |
Hashimoto's thyroiditis | 0.8 | 1.2 | -0.5 |
Hemorrhoidal disease, Hemorrhoids, Piles | 0.3 | -0.3 | |
Hidradenitis Suppurativa | 0.4 | -0.4 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.8 | -3 |
hypercholesterolemia (High Cholesterol) | 1 | 0.6 | 0.67 |
hyperglycemia | 1.8 | 0.5 | 2.6 |
Hyperlipidemia (High Blood Fats) | 0.8 | 1.2 | -0.5 |
hypertension (High Blood Pressure | 2.2 | 3.6 | -0.64 |
Hypoxia | 0.2 | 1.2 | -5 |
IgA nephropathy (IgAN) | 1.2 | 0.6 | 1 |
Inflammatory Bowel Disease | 1.8 | 2 | -0.11 |
Insomnia | 1.4 | 1.2 | 0.17 |
Intelligence | 1.6 | 0.2 | 7 |
Intracranial aneurysms | 0.6 | -0.6 | |
Irritable Bowel Syndrome | 2.9 | 3.6 | -0.24 |
Liver Cirrhosis | 2.1 | 2.6 | -0.24 |
Long COVID | 4.4 | 6 | -0.36 |
Lung Cancer | 0.2 | 0.2 | 0 |
ME/CFS with IBS | 0.6 | 0.6 | |
ME/CFS without IBS | 0.6 | 0.2 | 2 |
Menopause | 0.2 | 0.2 | 0 |
Metabolic Syndrome | 6.2 | 7 | -0.13 |
Mood Disorders | 6 | 7.2 | -0.2 |
multiple chemical sensitivity [MCS] | 0.6 | 0.6 | 0 |
Multiple Sclerosis | 3.3 | 3 | 0.1 |
Multiple system atrophy (MSA) | 0.5 | 0.8 | -0.6 |
Neuropathy (all types) | 0.6 | -0.6 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.6 | 0.33 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2 | 0.8 | 1.5 |
Obesity | 3.9 | 5.6 | -0.44 |
obsessive-compulsive disorder | 1.9 | 2.2 | -0.16 |
Osteoarthritis | 0.6 | -0.6 | |
Osteoporosis | 1.6 | 1.2 | 0.33 |
Parkinson's Disease | 1.4 | 3.7 | -1.64 |
Polycystic ovary syndrome | 0.9 | 3.6 | -3 |
primary biliary cholangitis | 0.2 | 0.2 | |
Psoriasis | 1.7 | 1.6 | 0.06 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 4.6 | -0.92 |
Schizophrenia | 0.8 | 3.6 | -3.5 |
scoliosis | 0.2 | 0.8 | -3 |
Sjögren syndrome | 1 | 0.2 | 4 |
Sleep Apnea | 0.6 | 0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1 | -1 | |
Stress / posttraumatic stress disorder | 1.5 | 3.1 | -1.07 |
Systemic Lupus Erythematosus | 1.3 | 2.2 | -0.69 |
Tic Disorder | 1.3 | 0.9 | 0.44 |
Tourette syndrome | 0.6 | 0.8 | -0.33 |
Type 1 Diabetes | 0.9 | 2 | -1.22 |
Type 2 Diabetes | 4.7 | 5.6 | -0.19 |
Ulcerative colitis | 4.8 | 1.8 | 1.67 |
Unhealthy Ageing | 0.8 | 1.3 | -0.63 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.